Wexler Wallace Appointed Co-Lead Counsel in Celebrex
Wexler Wallace LLP, along with co-counsel from Spector Roseman Kodroff & Willis PC, has been named co-lead counsel for a proposed class of end-payors in the case In re Celebrex Antitrust Litigation. Judge Arenda L. Wright Allen entered the order on April 13. The complaint, which was filed in the Eastern District of Virginia, alleges that defendant Pfizer, Inc. and its subsidiaries implemented an unlawful scheme to suppress generic competition for the drug Celebrex. Click here for more information about the Celebrex antitrust litigation. You can read more about Wexler Wallace’s antitrust litigation practice here.